NewcelX Aktie 144229789 / CH1442297896
3.94
USD
-0.12
USD
-2.96 %
07.11.2025
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
NewcelX Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | NewcelX AG | 0.00 | 0.00 | USD |
| 2023 | NewcelX AG | 0.00 | 0.00 | USD |
| 2022 | NewcelX AG | 0.00 | 0.00 | USD |
| 2021 | NewcelX AG | 0.00 | 0.00 | USD |
| 2020 | NewcelX AG | - | - | USD |
| 2019 | NewcelX AG | - | - | USD |
| 2018 | NewcelX AG | - | - | USD |
Zu diesem Datensatz liegen uns leider keine Daten vor.
NewcelX AG Termine
| Unternehmen | Event | Datum |
|---|
NewcelX AG vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Hauptversammlung | Annual General Meeting | 30.06.2023 |
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 4 | 4 | 6 | 6 | 2 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Bilanz (in Mio. USD) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 0 | 0 | 0 | 6 | 9 |
| Summe Anlagevermögen | 0 | 0 | 1 | 0 | 0 |
| Summe Aktiva | 0 | 1 | 1 | 6 | 9 |
Bilanz (in Mio. USD) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 9 | 7 | 10 | 5 | 6 |
| Summe Eigenkapital | -9 | -6 | -9 | 1 | 3 |
| Summe Passiva | 0 | 1 | 1 | 6 | 9 |
Adresse
| The Circle 6, 8058 Kloten | |
| Telefon | +41 (44) 512-21-50 |
| URL | http://newcelx.net |
Management
|
Alexander C. Zwyer
Director |
|
Ariel Revel
Director-Medical Affairs |
|
Eran Israel Iohan
Independent Director |
|
Eric Konofal
Head-DOXA Program |
|
Kfir Molakandov
Vice President-Research & Development |
|
Liora Oren
Independent Director |
|
Michel Revel
Director & Chief Scientific Officer |
|
Olivier Samuel
Independent Director |
|
Ronen Twito
Executive Chairman & Chief Executive Officer |
|
Sarah Bazak
Investor Relation Contact |
|
Tamar Galili
Director |
|
Uri Ben-Or
Chief Financial Officer |